Jade Biosciences Inc. Company Profile
NASDAQ: JBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Jade Biosciences at a glance
Jade Biosciences Inc. (NASDAQ: JBIO) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Waltham, MA. Jade Biosciences is led by Mr. Tom Frohlich and employs about 55 people. The company's shares have traded publicly since 2021.
At a market capitalization of $899.9 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001798749, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Jade Biosciences do?
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Jade Biosciences Inc.
- Ticker
- NASDAQ: JBIO
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Tom Frohlich
- Employees
- 55
- Headquarters
- Building 23, Waltham, MA, United States
- Phone
- 781 312 3013
- Website
- jadebiosciences.com
- IPO year
- 2021
- Market cap
- $899.90M
- SEC CIK
- 0001798749
- Latest annual report
- 10-K · Mar 6, 2026
Companies similar to Jade Biosciences
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MLTXMoonLake Immunotherapeutics Class A | 10.58 | -1.76% | $900.43M | vs JBIO |
| ALMSAlumis Inc. | 6.97 | +2.95% | $902.16M | vs JBIO |
| RIGLRigel Pharmaceuticals Inc. | 48.72 | +1.52% | $910.08M | vs JBIO |
| KURAKura Oncology Inc. | 10.52 | -1.41% | $935.87M | vs JBIO |
| CRVSCorvus Pharmaceuticals Inc. | 10.21 | -1.92% | $858.87M | vs JBIO |
| ANROAlto Neuroscience Inc. | 24.03 | +2.17% | $942.99M | vs JBIO |
| CYRXCryoPort Inc. | 16.90 | -2.59% | $855.97M | vs JBIO |
| SPTXSeaport Therapeutics Inc. | 17.91 | -0.11% | $958.73M | vs JBIO |